|
||||||
|
Editing gene: FTX (ImmuneEditome ID:100302692) |
1. Gene summary of enriched editing regions for FTX |
 Gene summary |
| Gene information | Gene symbol | FTX | Gene ID | 100302692 | ||||||||||||
| GeneSynonyms | LINC00182|MIR374AHG|NCRNA00182 | |||||||||||||||
| GeneCytomap | Xq13.2 | |||||||||||||||
| GeneType | ncRNA | |||||||||||||||
| GeneDescription | FTX transcript, XIST regulator (non-protein coding)|five prime to XIST|mir-374a-545 cluster host gene (non-protein coding) | |||||||||||||||
| GeneModificationdate | 20230509 | |||||||||||||||
| UniprotID | . | |||||||||||||||
| PubMed ID |
| UCSC image. |
 |
| Locations of each EERs. |
| EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure |
| chrX:74196749-74197932:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | L1MA9 | chrX:74196749-74197932:-.alignment |
| chrX:74196749-74197932:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | L1MA9 | chrX:74196749-74197932:-.alignment |
| chrX:74196749-74197932:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | L1MA9 | chrX:74196749-74197932:-.alignment |
| chrX:74208227-74208998:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSx,AluJr,AluJb | chrX:74208227-74208998:-.alignment |
| chrX:74208227-74208998:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSx,AluJr,AluJb | chrX:74208227-74208998:-.alignment |
| chrX:74208227-74208998:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSx,AluJr,AluJb | chrX:74208227-74208998:-.alignment |
| chrX:74214258-74214491:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSz | chrX:74214258-74214491:-.alignment |
| chrX:74214258-74214491:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSz | chrX:74214258-74214491:-.alignment |
| chrX:74214258-74214491:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSz | chrX:74214258-74214491:-.alignment |
| chrX:74216814-74217060:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSx | chrX:74216814-74217060:-.alignment |
| chrX:74216814-74217060:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSx | chrX:74216814-74217060:-.alignment |
| chrX:74216814-74217060:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSx | chrX:74216814-74217060:-.alignment |
| chrX:74221576-74223936:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,(AAGG)n,(T)n,FLAM_C,L3,AluSz,MIRc,MIR3,(TACC)n,MIRb | chrX:74221576-74223936:-.alignment |
| chrX:74221576-74223936:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,(AAGG)n,(T)n,FLAM_C,L3,AluSz,MIRc,MIR3,(TACC)n,MIRb | chrX:74221576-74223936:-.alignment |
| chrX:74221576-74223936:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,(AAGG)n,(T)n,FLAM_C,L3,AluSz,MIRc,MIR3,(TACC)n,MIRb | chrX:74221576-74223936:-.alignment |
| chrX:74224974-74226827:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluSx1,L1MB7 | chrX:74224974-74226827:-.alignment |
| chrX:74224974-74226827:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluSx1,L1MB7 | chrX:74224974-74226827:-.alignment |
| chrX:74224974-74226827:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluSx1,L1MB7 | chrX:74224974-74226827:-.alignment |
| chrX:74228399-74228673:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSp | chrX:74228399-74228673:-.alignment |
| chrX:74228399-74228673:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSp | chrX:74228399-74228673:-.alignment |
| chrX:74228399-74228673:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSp | chrX:74228399-74228673:-.alignment |
| chrX:74243376-74244007:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSz,AluSx | chrX:74243376-74244007:-.alignment |
| chrX:74243376-74244007:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSz,AluSx | chrX:74243376-74244007:-.alignment |
| chrX:74243376-74244007:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluSz,AluSx | chrX:74243376-74244007:-.alignment |
| chrX:74248115-74248345:- | ENST00000430772.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJr4 | chrX:74248115-74248345:-.alignment |
| chrX:74248115-74248345:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJr4 | chrX:74248115-74248345:-.alignment |
| chrX:74248115-74248345:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJr4 | chrX:74248115-74248345:-.alignment |
| chrX:74248115-74248345:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJr4 | chrX:74248115-74248345:-.alignment |
| chrX:74260775-74262055:- | ENST00000430772.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluJo,AluSz6,MamRep605 | chrX:74260775-74262055:-.alignment |
| chrX:74260775-74262055:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluJo,AluSz6,MamRep605 | chrX:74260775-74262055:-.alignment |
| chrX:74260775-74262055:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluJo,AluSz6,MamRep605 | chrX:74260775-74262055:-.alignment |
| chrX:74260775-74262055:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | AluJb,AluJo,AluSz6,MamRep605 | chrX:74260775-74262055:-.alignment |
| chrX:74263487-74266556:- | ENST00000430772.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | MER20B,MER58B,AluSx1,L1MB2,AluSp,(T)n,AluJb,AluJo,AluSz | chrX:74263487-74266556:-.alignment |
| chrX:74263487-74266556:- | ENST00000602420.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | MER20B,MER58B,AluSx1,L1MB2,AluSp,(T)n,AluJb,AluJo,AluSz | chrX:74263487-74266556:-.alignment |
| chrX:74263487-74266556:- | ENST00000602812.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | MER20B,MER58B,AluSx1,L1MB2,AluSp,(T)n,AluJb,AluJo,AluSz | chrX:74263487-74266556:-.alignment |
| chrX:74263487-74266556:- | ENST00000603672.4 | ENSG00000230590.6 | FTX | ncRNA_intronic | MER20B,MER58B,AluSx1,L1MB2,AluSp,(T)n,AluJb,AluJo,AluSz | chrX:74263487-74266556:-.alignment |
| chrX:74274950-74280179:- | ENST00000429124.4 | ENSG00000230590.6 | FTX | ncRNA_exonic | AluSx3,FLAM_C,AluJo,(T)n,AluJr,AluSc,AluJb,AluSg,MER58A,A-rich,MIRb | chrX:74274950-74280179:-.alignment |
Top |
2. Tumor-specific enriched editing regions for FTX |
 |
| Comparison of enriched editing regions between tumor and normal. |
| * P<0.05 and Informative number >=20. |
| * EER: enriched editing region, EAG: EER-associated genes. |
| ID_events | cancer | Type | P | Boxplot |
| chrX:74196749-74197932:- | BRCA | EER | 8.0752e-07 |  |
| chrX:74208227-74208998:- | BRCA | EER | 1.1213e-02 |  |
| ENSG00000230590.6,FTX | BRCA | EAG | 9.0721e-07 |  |
| chrX:74196749-74197932:- | KIRC | EER | 6.9556e-04 |  |
| ENSG00000230590.6,FTX | KIRC | EAG | 4.2959e-03 |  |
| ENSG00000230590.6,FTX | LIHC | EAG | 2.1330e-02 |  |
| chrX:74196749-74197932:- | LUSC | EER | 9.9581e-06 |  |
| chrX:74263487-74266556:- | LUSC | EER | 2.3463e-02 |  |
| ENSG00000230590.6,FTX | LUSC | EAG | 5.1856e-07 |  |
| ENSG00000230590.6,FTX | STAD | EAG | 1.0762e-02 |  |
| chrX:74196749-74197932:- | THCA | EER | 1.9161e-08 |  |
| ENSG00000230590.6,FTX | THCA | EAG | 7.4524e-09 |  |
| chrX:74196749-74197932:- | UCEC | EER | 3.2974e-02 |  |
| ENSG00000230590.6,FTX | UCEC | EAG | 3.4269e-03 |  |
Top |
| Correlation of enriched editing regions with tumor stages. |
| * AnovaP<0.05, Pearson P<0.05 and Informative number >=20. |
| * EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage. |
| * Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page. |
| ID_events | cancer | Type | StageType | AnovaP | P | R | Boxplot |
| chrX:74196749-74197932:- | BLCA | Path | EER | 1.1648e-02 | 1.8655e-02 | 0.1255 |  |
| chrX:74208227-74208998:- | BRCA | Path | EER | 4.3608e-02 | 2.2917e-02 | 0.1709 |  |
| chrX:74221576-74223936:- | ESCA | Path | EER | 7.4658e-03 | 3.5642e-02 | 0.1904 |  |
| chrX:74221576-74223936:- | KIRC | Path | EER | 2.0640e-02 | 3.4310e-02 | -0.2151 |  |
| chrX:74196749-74197932:- | KIRP | Path | EER | 2.3764e-02 | 7.4156e-03 | 0.1826 |  |
| ENSG00000230590.6,FTX | KIRP | Cli | EAG | 1.7368e-02 | 2.4479e-03 | 0.2270 |  |
| chrX:74221576-74223936:- | KIRP | Cli | EER | 3.3652e-03 | 1.2977e-03 | 0.6413 |  |
| ENSG00000230590.6,FTX | PAAD | Path | EAG | 4.6327e-02 | 1.4027e-02 | 0.1870 |  |
| chrX:74263487-74266556:- | PAAD | Path | EER | 2.9483e-02 | 4.3784e-02 | 0.1778 |  |
| ENSG00000230590.6,FTX | SKCM | Path | EAG | 7.8760e-03 | 6.2769e-04 | 0.1904 |  |
| chrX:74196749-74197932:- | THCA | Path | EER | 2.9744e-02 | 2.6903e-02 | 0.0997 |  |
| ENSG00000230590.6,FTX | THCA | Path | EAG | 5.0491e-03 | 1.6207e-03 | 0.1403 |  |
Top |
| Associations of enriched editing regions with cancer survival. |
| * Pkm<0.05 and Pcox<0.05. |
| * EER: enriched editing region, EAG: EER-associated genes. |
| ID_events | cancer | TypeID | Pkm | Pcox_continuous | HR_continuous | KMPlot |
| chrX:74263487-74266556:- | CESC | EER | 3.2522e-02 | 2.6861e-03 | 1.1695e+02 |  |
| ENSG00000230590.6,FTX | DLBC | EAG | 3.5327e-02 | 4.0123e-02 | 1.1959e-04 |  |
| chrX:74263487-74266556:- | HNSC | EER | 1.4971e-02 | 1.2690e-04 | 6.1610e-03 |  |
| chrX:74263487-74266556:- | LAML | EER | 2.6869e-03 | 4.8010e-03 | 6.4733e+02 |  |
| ENSG00000230590.6,FTX | LAML | EAG | 9.1623e-03 | 4.2128e-02 | 1.8832e+05 |  |
Top |
3. Enriched editing regions and immune related genes for FTX |
 |
| Enriched editing regions and immune related genes. |
| * First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05). |
| * Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets. |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page. |
| ID_events | cancer | Type | Gene | beta | FDR | PearsonP | PearsonR | CorrelationPlot | RBP | RBPtargets | ImmuneGene | ImmuneFraction | HallMark |
| chrX:74196749-74197932:- | BLCA | EER | ENSG00000106268,NUDT1 | 0.2504 | 6.3611e-05 | 3.1944e-15 | 0.4041 |  | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_DNA_REPAIR |
| chrX:74196749-74197932:- | BLCA | EER | ENSG00000142684,ZNF593 | 0.1498 | 2.9179e-02 | 4.7103e-16 | 0.4151 |  | N | N | NA | NK_cells_activated | GSVA_HALLMARK_UV_RESPONSE_DN |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000173209,AHSA2 | -0.4851 | 3.4405e-24 | 5.6030e-22 | -0.4282 |  | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000004534,RBM6 | -0.4665 | 4.2148e-22 | 1.5342e-21 | -0.4240 |  | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000214021,TTLL3 | -0.4626 | 5.6983e-22 | 6.7179e-20 | -0.4078 |  | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000133624,ZNF767P | -0.4575 | 2.9895e-21 | 3.5984e-20 | -0.4105 |  | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000117616,RSRP1 | -0.4545 | 6.4773e-21 | 2.4287e-19 | -0.4021 |  | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000003756,RBM5 | -0.4482 | 3.9425e-20 | 2.5030e-20 | -0.4121 |  | N | N | RBM5 | T_cells_CD4_memory_resting | GSVA_HALLMARK_GLYCOLYSIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000007545,CRAMP1L | -0.4226 | 1.6104e-17 | 3.7741e-19 | -0.4001 |  | N | N | NA | T_cells_CD4_memory_activated | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74196749-74197932:- | LUSC | EER | ENSG00000114857,NKTR | -0.4461 | 3.0556e-16 | 2.1616e-17 | -0.4047 |  | N | N | NKTR | B_cells_memory | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | BLCA | EER | ENSG00000106268,NUDT1 | 0.2504 | 6.3611e-05 | 3.1944e-15 | 0.4041 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_DNA_REPAIR |
| chrX:74196749-74197932:- | BLCA | EER | ENSG00000142684,ZNF593 | 0.1498 | 2.9179e-02 | 4.7103e-16 | 0.4151 | | N | N | NA | NK_cells_activated | GSVA_HALLMARK_UV_RESPONSE_DN |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000173209,AHSA2 | -0.4851 | 3.4405e-24 | 5.6030e-22 | -0.4282 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000004534,RBM6 | -0.4665 | 4.2148e-22 | 1.5342e-21 | -0.4240 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000214021,TTLL3 | -0.4626 | 5.6983e-22 | 6.7179e-20 | -0.4078 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000133624,ZNF767P | -0.4575 | 2.9895e-21 | 3.5984e-20 | -0.4105 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000117616,RSRP1 | -0.4545 | 6.4773e-21 | 2.4287e-19 | -0.4021 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000003756,RBM5 | -0.4482 | 3.9425e-20 | 2.5030e-20 | -0.4121 | | N | N | RBM5 | T_cells_CD4_memory_resting | GSVA_HALLMARK_GLYCOLYSIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000007545,CRAMP1L | -0.4226 | 1.6104e-17 | 3.7741e-19 | -0.4001 | | N | N | NA | T_cells_CD4_memory_activated | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74196749-74197932:- | LUSC | EER | ENSG00000114857,NKTR | -0.4461 | 3.0556e-16 | 2.1616e-17 | -0.4047 | | N | N | NKTR | B_cells_memory | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | BLCA | EER | ENSG00000106268,NUDT1 | 0.2504 | 6.3611e-05 | 3.1944e-15 | 0.4041 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_DNA_REPAIR |
| chrX:74196749-74197932:- | BLCA | EER | ENSG00000142684,ZNF593 | 0.1498 | 2.9179e-02 | 4.7103e-16 | 0.4151 | | N | N | NA | NK_cells_activated | GSVA_HALLMARK_UV_RESPONSE_DN |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000173209,AHSA2 | -0.4851 | 3.4405e-24 | 5.6030e-22 | -0.4282 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000004534,RBM6 | -0.4665 | 4.2148e-22 | 1.5342e-21 | -0.4240 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000214021,TTLL3 | -0.4626 | 5.6983e-22 | 6.7179e-20 | -0.4078 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000133624,ZNF767P | -0.4575 | 2.9895e-21 | 3.5984e-20 | -0.4105 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000117616,RSRP1 | -0.4545 | 6.4773e-21 | 2.4287e-19 | -0.4021 | | N | N | NA | T_cells_CD4_naive | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000003756,RBM5 | -0.4482 | 3.9425e-20 | 2.5030e-20 | -0.4121 | | N | N | RBM5 | T_cells_CD4_memory_resting | GSVA_HALLMARK_GLYCOLYSIS |
| chrX:74196749-74197932:- | LUAD | EER | ENSG00000007545,CRAMP1L | -0.4226 | 1.6104e-17 | 3.7741e-19 | -0.4001 | | N | N | NA | T_cells_CD4_memory_activated | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74196749-74197932:- | LUSC | EER | ENSG00000114857,NKTR | -0.4461 | 3.0556e-16 | 2.1616e-17 | -0.4047 | | N | N | NKTR | B_cells_memory | GSVA_HALLMARK_ADIPOGENESIS |
| chrX:74208227-74208998:- | ESCA | EER | ENSG00000173889,PHC3 | -0.4045 | 3.5855e-03 | 5.8227e-06 | -0.4021 |  | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000105127,AKAP8 | 0.3736 | 2.6360e-02 | 1.0506e-08 | 0.4618 |  | N | N | NA | Eosinophils | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000174871,CNIH2 | 0.3581 | 3.4005e-02 | 2.0412e-11 | 0.5296 |  | N | N | NA | B_cells_naive | GSVA_HALLMARK_KRAS_SIGNALING_DN |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000245156,RP11-867G23.3 | 0.3533 | 3.8403e-02 | 1.3710e-11 | 0.5334 |  | N | N | NA | B_cells_memory | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000141994,DUS3L | 0.3541 | 3.9113e-02 | 7.2308e-08 | 0.4375 |  | N | N | NA | B_cells_naive | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000279520,RP11-20I23.2 | 0.3496 | 4.2607e-02 | 2.6752e-11 | 0.5269 |  | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB |
| chrX:74208227-74208998:- | ESCA | EER | ENSG00000173889,PHC3 | -0.4045 | 3.5855e-03 | 5.8227e-06 | -0.4021 | | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000105127,AKAP8 | 0.3736 | 2.6360e-02 | 1.0506e-08 | 0.4618 | | N | N | NA | Eosinophils | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000174871,CNIH2 | 0.3581 | 3.4005e-02 | 2.0412e-11 | 0.5296 | | N | N | NA | B_cells_naive | GSVA_HALLMARK_KRAS_SIGNALING_DN |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000245156,RP11-867G23.3 | 0.3533 | 3.8403e-02 | 1.3710e-11 | 0.5334 | | N | N | NA | B_cells_memory | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000141994,DUS3L | 0.3541 | 3.9113e-02 | 7.2308e-08 | 0.4375 | | N | N | NA | B_cells_naive | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000279520,RP11-20I23.2 | 0.3496 | 4.2607e-02 | 2.6752e-11 | 0.5269 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB |
| chrX:74208227-74208998:- | ESCA | EER | ENSG00000173889,PHC3 | -0.4045 | 3.5855e-03 | 5.8227e-06 | -0.4021 | | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000105127,AKAP8 | 0.3736 | 2.6360e-02 | 1.0506e-08 | 0.4618 | | N | N | NA | Eosinophils | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000174871,CNIH2 | 0.3581 | 3.4005e-02 | 2.0412e-11 | 0.5296 | | N | N | NA | B_cells_naive | GSVA_HALLMARK_KRAS_SIGNALING_DN |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000245156,RP11-867G23.3 | 0.3533 | 3.8403e-02 | 1.3710e-11 | 0.5334 | | N | N | NA | B_cells_memory | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000141994,DUS3L | 0.3541 | 3.9113e-02 | 7.2308e-08 | 0.4375 | | N | N | NA | B_cells_naive | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74208227-74208998:- | LAML | EER | ENSG00000279520,RP11-20I23.2 | 0.3496 | 4.2607e-02 | 2.6752e-11 | 0.5269 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000127481,UBR4 | -0.4455 | 6.3014e-03 | 1.5462e-07 | -0.4486 |  | N | N | NA | Monocytes | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000114902,SPCS1 | 0.4394 | 7.8466e-03 | 1.1163e-06 | 0.4195 |  | N | N | NA | NK_cells_resting | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000006625,GGCT | 0.4237 | 9.7733e-03 | 6.9168e-07 | 0.4268 |  | N | N | NA | NK_cells_resting | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000106355,LSM5 | 0.4227 | 1.0793e-02 | 1.6494e-06 | 0.4134 |  | N | N | NA | NK_cells_resting | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000173064,HECTD4 | -0.4157 | 1.3213e-02 | 1.6633e-07 | -0.4476 |  | N | N | NA | Monocytes | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000169057,MECP2 | -0.4040 | 1.7302e-02 | 1.2488e-06 | -0.4178 |  | N | N | NA | Monocytes | GSVA_HALLMARK_MTORC1_SIGNALING |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000143442,POGZ | -0.3964 | 2.0785e-02 | 1.0406e-06 | -0.4206 |  | N | N | NA | Monocytes | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000089916,GPATCH2L | -0.3914 | 2.3112e-02 | 5.4949e-07 | -0.4303 |  | N | N | NA | Monocytes | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000196262,PPIA | 0.3761 | 3.2017e-02 | 2.4214e-06 | 0.4074 |  | N | N | PPIA | Macrophages_M2 | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000136315,RP11-84C10.2 | 0.3613 | 4.4148e-02 | 2.4941e-09 | 0.5018 |  | N | N | NA | Monocytes | GSVA_HALLMARK_MTORC1_SIGNALING |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000127481,UBR4 | -0.4455 | 6.3014e-03 | 1.5462e-07 | -0.4486 | | N | N | NA | Monocytes | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000114902,SPCS1 | 0.4394 | 7.8466e-03 | 1.1163e-06 | 0.4195 | | N | N | NA | NK_cells_resting | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000006625,GGCT | 0.4237 | 9.7733e-03 | 6.9168e-07 | 0.4268 | | N | N | NA | NK_cells_resting | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000106355,LSM5 | 0.4227 | 1.0793e-02 | 1.6494e-06 | 0.4134 | | N | N | NA | NK_cells_resting | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000173064,HECTD4 | -0.4157 | 1.3213e-02 | 1.6633e-07 | -0.4476 | | N | N | NA | Monocytes | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000169057,MECP2 | -0.4040 | 1.7302e-02 | 1.2488e-06 | -0.4178 | | N | N | NA | Monocytes | GSVA_HALLMARK_MTORC1_SIGNALING |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000143442,POGZ | -0.3964 | 2.0785e-02 | 1.0406e-06 | -0.4206 | | N | N | NA | Monocytes | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000089916,GPATCH2L | -0.3914 | 2.3112e-02 | 5.4949e-07 | -0.4303 | | N | N | NA | Monocytes | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000196262,PPIA | 0.3761 | 3.2017e-02 | 2.4214e-06 | 0.4074 | | N | N | PPIA | Macrophages_M2 | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000136315,RP11-84C10.2 | 0.3613 | 4.4148e-02 | 2.4941e-09 | 0.5018 | | N | N | NA | Monocytes | GSVA_HALLMARK_MTORC1_SIGNALING |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000127481,UBR4 | -0.4455 | 6.3014e-03 | 1.5462e-07 | -0.4486 | | N | N | NA | Monocytes | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000114902,SPCS1 | 0.4394 | 7.8466e-03 | 1.1163e-06 | 0.4195 | | N | N | NA | NK_cells_resting | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000006625,GGCT | 0.4237 | 9.7733e-03 | 6.9168e-07 | 0.4268 | | N | N | NA | NK_cells_resting | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000106355,LSM5 | 0.4227 | 1.0793e-02 | 1.6494e-06 | 0.4134 | | N | N | NA | NK_cells_resting | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000173064,HECTD4 | -0.4157 | 1.3213e-02 | 1.6633e-07 | -0.4476 | | N | N | NA | Monocytes | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000169057,MECP2 | -0.4040 | 1.7302e-02 | 1.2488e-06 | -0.4178 | | N | N | NA | Monocytes | GSVA_HALLMARK_MTORC1_SIGNALING |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000143442,POGZ | -0.3964 | 2.0785e-02 | 1.0406e-06 | -0.4206 | | N | N | NA | Monocytes | GSVA_HALLMARK_PANCREAS_BETA_CELLS |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000089916,GPATCH2L | -0.3914 | 2.3112e-02 | 5.4949e-07 | -0.4303 | | N | N | NA | Monocytes | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000196262,PPIA | 0.3761 | 3.2017e-02 | 2.4214e-06 | 0.4074 | | N | N | PPIA | Macrophages_M2 | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION |
| chrX:74214258-74214491:- | LAML | EER | ENSG00000136315,RP11-84C10.2 | 0.3613 | 4.4148e-02 | 2.4941e-09 | 0.5018 | | N | N | NA | Monocytes | GSVA_HALLMARK_MTORC1_SIGNALING |
| chrX:74221576-74223936:- | ESCA | EER | ENSG00000123908,AGO2 | 0.3319 | 1.3757e-02 | 9.4282e-08 | 0.4354 |  | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74221576-74223936:- | ESCA | EER | ENSG00000240163,RP11-745A24.1 | 0.3016 | 2.8741e-02 | 3.2757e-07 | 0.4184 |  | N | N | NA | Plasma_cells | GSVA_HALLMARK_SPERMATOGENESIS |
| chrX:74221576-74223936:- | ESCA | EER | ENSG00000123908,AGO2 | 0.3319 | 1.3757e-02 | 9.4282e-08 | 0.4354 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74221576-74223936:- | ESCA | EER | ENSG00000240163,RP11-745A24.1 | 0.3016 | 2.8741e-02 | 3.2757e-07 | 0.4184 | | N | N | NA | Plasma_cells | GSVA_HALLMARK_SPERMATOGENESIS |
| chrX:74221576-74223936:- | ESCA | EER | ENSG00000123908,AGO2 | 0.3319 | 1.3757e-02 | 9.4282e-08 | 0.4354 | | N | N | NA | T_cells_CD4_memory_resting | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74221576-74223936:- | ESCA | EER | ENSG00000240163,RP11-745A24.1 | 0.3016 | 2.8741e-02 | 3.2757e-07 | 0.4184 | | N | N | NA | Plasma_cells | GSVA_HALLMARK_SPERMATOGENESIS |
| chrX:74224974-74226827:- | ESCA | EER | ENSG00000185100,ADSSL1 | 0.2950 | 3.1310e-02 | 2.0409e-07 | 0.4167 |  | N | N | NA | Dendritic_cells_resting | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE |
| chrX:74224974-74226827:- | ESCA | EER | ENSG00000185100,ADSSL1 | 0.2950 | 3.1310e-02 | 2.0409e-07 | 0.4167 | | N | N | NA | Dendritic_cells_resting | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE |
| chrX:74224974-74226827:- | ESCA | EER | ENSG00000185100,ADSSL1 | 0.2950 | 3.1310e-02 | 2.0409e-07 | 0.4167 | | N | N | NA | Dendritic_cells_resting | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE |
| chrX:74263487-74266556:- | LUAD | EER | ENSG00000090054,SPTLC1 | 0.3420 | 7.3314e-09 | 6.7309e-17 | 0.4153 |  | N | N | NA | T_cells_regulatory_(Tregs) | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233830,EIF4HP1 | 0.4172 | 1.4939e-04 | 9.0389e-08 | 0.4303 |  | N | N | NA | Macrophages_M0 | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000254612,RP11-676M6.1 | 0.4175 | 1.7938e-04 | 1.0845e-07 | 0.4279 |  | N | N | NA | GSVA_HALLMARK_SPERMATOGENESIS | |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000232024,LSM12P1 | 0.4126 | 2.2155e-04 | 4.4880e-07 | 0.4085 |  | N | N | NA | Mast_cells_activated | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000073905,VDAC1P1 | 0.4158 | 2.3905e-04 | 5.7893e-07 | 0.4049 |  | N | N | NA | T_cells_gamma_delta | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000230409,TCEA1P2 | 0.3957 | 5.2212e-04 | 2.4818e-07 | 0.4168 |  | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233111,RAB1C | 0.3320 | 5.4873e-03 | 2.2372e-07 | 0.4182 |  | N | N | NA | GSVA_HALLMARK_ADIPOGENESIS | |
| chrX:74263487-74266556:- | STAD | EER | ENSG00000105700,KXD1 | 0.2123 | 3.7254e-03 | 1.6360e-15 | 0.4215 |  | N | N | NA | T_cells_CD8 | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY |
| chrX:74263487-74266556:- | LUAD | EER | ENSG00000090054,SPTLC1 | 0.3420 | 7.3314e-09 | 6.7309e-17 | 0.4153 | | N | N | NA | T_cells_regulatory_(Tregs) | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233830,EIF4HP1 | 0.4172 | 1.4939e-04 | 9.0389e-08 | 0.4303 | | N | N | NA | Macrophages_M0 | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000254612,RP11-676M6.1 | 0.4175 | 1.7938e-04 | 1.0845e-07 | 0.4279 | | N | N | NA | GSVA_HALLMARK_SPERMATOGENESIS | |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000232024,LSM12P1 | 0.4126 | 2.2155e-04 | 4.4880e-07 | 0.4085 | | N | N | NA | Mast_cells_activated | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000073905,VDAC1P1 | 0.4158 | 2.3905e-04 | 5.7893e-07 | 0.4049 | | N | N | NA | T_cells_gamma_delta | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000230409,TCEA1P2 | 0.3957 | 5.2212e-04 | 2.4818e-07 | 0.4168 | | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233111,RAB1C | 0.3320 | 5.4873e-03 | 2.2372e-07 | 0.4182 | | N | N | NA | GSVA_HALLMARK_ADIPOGENESIS | |
| chrX:74263487-74266556:- | STAD | EER | ENSG00000105700,KXD1 | 0.2123 | 3.7254e-03 | 1.6360e-15 | 0.4215 | | N | N | NA | T_cells_CD8 | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY |
| chrX:74263487-74266556:- | LUAD | EER | ENSG00000090054,SPTLC1 | 0.3420 | 7.3314e-09 | 6.7309e-17 | 0.4153 | | N | N | NA | T_cells_regulatory_(Tregs) | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233830,EIF4HP1 | 0.4172 | 1.4939e-04 | 9.0389e-08 | 0.4303 | | N | N | NA | Macrophages_M0 | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000254612,RP11-676M6.1 | 0.4175 | 1.7938e-04 | 1.0845e-07 | 0.4279 | | N | N | NA | GSVA_HALLMARK_SPERMATOGENESIS | |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000232024,LSM12P1 | 0.4126 | 2.2155e-04 | 4.4880e-07 | 0.4085 | | N | N | NA | Mast_cells_activated | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000073905,VDAC1P1 | 0.4158 | 2.3905e-04 | 5.7893e-07 | 0.4049 | | N | N | NA | T_cells_gamma_delta | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000230409,TCEA1P2 | 0.3957 | 5.2212e-04 | 2.4818e-07 | 0.4168 | | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233111,RAB1C | 0.3320 | 5.4873e-03 | 2.2372e-07 | 0.4182 | | N | N | NA | GSVA_HALLMARK_ADIPOGENESIS | |
| chrX:74263487-74266556:- | STAD | EER | ENSG00000105700,KXD1 | 0.2123 | 3.7254e-03 | 1.6360e-15 | 0.4215 | | N | N | NA | T_cells_CD8 | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY |
| chrX:74263487-74266556:- | LUAD | EER | ENSG00000090054,SPTLC1 | 0.3420 | 7.3314e-09 | 6.7309e-17 | 0.4153 | | N | N | NA | T_cells_regulatory_(Tregs) | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233830,EIF4HP1 | 0.4172 | 1.4939e-04 | 9.0389e-08 | 0.4303 | | N | N | NA | Macrophages_M0 | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000254612,RP11-676M6.1 | 0.4175 | 1.7938e-04 | 1.0845e-07 | 0.4279 | | N | N | NA | GSVA_HALLMARK_SPERMATOGENESIS | |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000232024,LSM12P1 | 0.4126 | 2.2155e-04 | 4.4880e-07 | 0.4085 | | N | N | NA | Mast_cells_activated | GSVA_HALLMARK_MYC_TARGETS_V1 |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000073905,VDAC1P1 | 0.4158 | 2.3905e-04 | 5.7893e-07 | 0.4049 | | N | N | NA | T_cells_gamma_delta | GSVA_HALLMARK_ANDROGEN_RESPONSE |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000230409,TCEA1P2 | 0.3957 | 5.2212e-04 | 2.4818e-07 | 0.4168 | | N | N | NA | Mast_cells_resting | GSVA_HALLMARK_PROTEIN_SECRETION |
| chrX:74263487-74266556:- | GBM | EER | ENSG00000233111,RAB1C | 0.3320 | 5.4873e-03 | 2.2372e-07 | 0.4182 | | N | N | NA | GSVA_HALLMARK_ADIPOGENESIS | |
| chrX:74263487-74266556:- | STAD | EER | ENSG00000105700,KXD1 | 0.2123 | 3.7254e-03 | 1.6360e-15 | 0.4215 | | N | N | NA | T_cells_CD8 | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY |
More results |
Top |
4. Enriched editing regions and immune related splicing for FTX |
 |
| Enriched editing regions and immune related splicing. |
| * First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05). |
| * Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets. |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page. |
| ID_events | cancer | Type | SplicingType | SplicingGene | SplicingChr | SplicingPosition | beta | FDR | PearsonP | PearsonR | CorrelationPlot | RBP | RBPtargets | ImmuneGene | ImmuneFraction | HallMark |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000205581.6 | chr21 | 39345145:39347483:39348291:39348339 | -0.3629 | 1.3048e-10 | 1.4396e-14 | -0.4190 |  | N | N | NA | T_cells_CD4_memory_activated | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000075413.13 | chr14 | 103498501:103498528:103502881:103503066 | -0.3354 | 7.3142e-10 | 1.2423e-13 | -0.4266 |  | N | N | MARK3 | T_cells_CD4_memory_activated | GSVA_HALLMARK_COAGULATION |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000164576.7 | chr5 | 154451090:154451213:154452455:154452495 | -0.3090 | 4.0254e-09 | 6.8310e-12 | -0.4066 |  | N | N | NA | T_cells_CD4_memory_activated | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000132780.12 | chr1 | 45609299:45610995:45613168:45613248 | -0.2994 | 1.2405e-07 | 4.6145e-13 | -0.4061 |  | N | N | NA | T_cells_CD4_memory_activated | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000108848.11 | chr17 | 50750500:50751362:50752199:50752282 | -0.2535 | 1.8852e-04 | 1.7654e-16 | -0.4212 |  | N | N | LUC7L3 | T_cells_regulatory_(Tregs) | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000113240.8 | chr5 | 178616881:178617434:178618555:178618778 | -0.3575 | 9.0317e-12 | 1.1957e-12 | -0.4026 |  | N | N | NA | T_cells_regulatory_(Tregs) | GSVA_HALLMARK_UV_RESPONSE_UP |
| chrX:74196749-74197932:- | BLCA | EER | IR | ENSG00000104852.10 | chr19 | 49102113:49102173:49104633:49104735 | -0.4025 | 2.0235e-11 | 2.7451e-16 | -0.4182 |  | N | N | NA | Macrophages_M1 | GSVA_HALLMARK_UV_RESPONSE_UP |
| ENSG00000230590.6,FTX | DLBC | EAG | IR | ENSG00000140400.10 | chr15 | 75356109:75356211:75356293:75356380 | -0.6685 | 3.5041e-02 | 1.0689e-05 | -0.6288 |  | N | ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184 | NA | Macrophages_M2 | GSVA_HALLMARK_MITOTIC_SPINDLE |
| ENSG00000230590.6,FTX | DLBC | EAG | MEX | ENSG00000104613.7 | chr8 | 19837080:19837160:19842847:19842927:19845703:19845797:19851648:19852083 | -0.7484 | 1.0138e-02 | 1.8088e-08 | -0.7365 |  | N | ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184 | NA | Macrophages_M2 | GSVA_HALLMARK_MITOTIC_SPINDLE |
| chrX:74224974-74226827:- | ESCA | EER | IR | ENSG00000111554.10 | chr12 | 68314947:68315265:68316077:68316253 | -0.3107 | 3.6484e-02 | 6.4161e-06 | -0.4036 |  | N | N | NA | Mast_cells_activated | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE |
More results |
Top |
5. Enriched editing regions and immune infiltration for FTX |
 |
| Associations of enriched editing regions with immune infiltration. |
| * P<0.05 and Informative number >=20. |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page. |
| ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
| ENSG00000230590.6,FTX | ACC | EAG | Dendritic_cells_resting | 2.1097e-03 | 0.3692 |  |
| chrX:74196749-74197932:- | BLCA | EER | Macrophages_M2 | 3.5938e-05 | 0.2187 |  |
| chrX:74221576-74223936:- | BLCA | EER | T_cells_gamma_delta | 4.6478e-04 | 0.4020 |  |
| chrX:74224974-74226827:- | BLCA | EER | Plasma_cells | 3.1002e-02 | -0.1792 |  |
| chrX:74263487-74266556:- | BLCA | EER | Macrophages_M1 | 2.2093e-04 | 0.2104 |  |
| ENSG00000230590.6,FTX | BLCA | EAG | T_cells_regulatory_(Tregs) | 2.1128e-04 | -0.1868 | .ENSG00000230590.6,FTX.png){kind=small} |
| chrX:74196749-74197932:- | BRCA | EER | B_cells_naive | 2.7162e-06 | -0.1435 |  |
| chrX:74208227-74208998:- | BRCA | EER | T_cells_follicular_helper | 3.5617e-02 | 0.1581 |  |
| chrX:74221576-74223936:- | BRCA | EER | T_cells_CD4_memory_resting | 1.8650e-02 | 0.2210 |  |
| chrX:74224974-74226827:- | BRCA | EER | Neutrophils | 1.9291e-02 | 0.2035 |  |
| chrX:74263487-74266556:- | BRCA | EER | T_cells_regulatory_(Tregs) | 2.2927e-02 | -0.1010 | .chrX_74263487-74266556_-.png){kind=small} |
| chrX:74274950-74280179:- | BRCA | EER | Macrophages_M1 | 3.4862e-03 | 0.3744 |  |
| ENSG00000230590.6,FTX | BRCA | EAG | B_cells_naive | 3.3966e-06 | -0.1409 |  |
| chrX:74196749-74197932:- | CESC | EER | B_cells_memory | 3.2782e-02 | 0.1281 |  |
| chrX:74263487-74266556:- | CESC | EER | Macrophages_M2 | 3.4283e-02 | 0.1444 |  |
| ENSG00000230590.6,FTX | CESC | EAG | Dendritic_cells_activated | 3.1758e-03 | 0.1695 |  |
| chrX:74196749-74197932:- | CHOL | EER | Macrophages_M2 | 3.7432e-02 | 0.3754 |  |
| chrX:74263487-74266556:- | CHOL | EER | T_cells_follicular_helper | 1.6732e-02 | 0.4934 |  |
| chrX:74208227-74208998:- | COAD | EER | Dendritic_cells_activated | 6.3980e-03 | -0.4190 |  |
| chrX:74224974-74226827:- | COAD | EER | Dendritic_cells_activated | 4.3722e-02 | 0.2613 |  |
| chrX:74274950-74280179:- | COAD | EER | T_cells_CD4_naive | 1.7514e-05 | 0.7697 |  |
| ENSG00000230590.6,FTX | COAD | EAG | T_cells_regulatory_(Tregs) | 9.6523e-03 | -0.1615 | .ENSG00000230590.6,FTX.png){kind=small} |
| chrX:74263487-74266556:- | DLBC | EER | Monocytes | 1.9840e-03 | 0.5683 |  |
| ENSG00000230590.6,FTX | DLBC | EAG | Macrophages_M2 | 1.9766e-03 | 0.4587 |  |
| chrX:74196749-74197932:- | ESCA | EER | T_cells_CD4_memory_resting | 4.4103e-04 | -0.2755 |  |
| chrX:74221576-74223936:- | ESCA | EER | Plasma_cells | 1.0050e-03 | 0.2770 |  |
| chrX:74228399-74228673:- | ESCA | EER | T_cells_CD4_memory_activated | 2.9282e-02 | 0.2941 |  |
| chrX:74260775-74262055:- | ESCA | EER | T_cells_regulatory_(Tregs) | 1.1254e-02 | -0.2618 | .chrX_74260775-74262055_-.png){kind=small} |
| chrX:74263487-74266556:- | ESCA | EER | T_cells_regulatory_(Tregs) | 4.2492e-04 | -0.2762 | .chrX_74263487-74266556_-.png){kind=small} |
| chrX:74274950-74280179:- | ESCA | EER | Plasma_cells | 5.2314e-03 | 0.2426 |  |
| ENSG00000230590.6,FTX | ESCA | EAG | T_cells_CD4_naive | 2.3471e-02 | -0.1785 |  |
| chrX:74263487-74266556:- | GBM | EER | Mast_cells_resting | 5.3548e-04 | 0.2870 |  |
| ENSG00000230590.6,FTX | GBM | EAG | Macrophages_M0 | 2.7400e-02 | -0.1723 |  |
| chrX:74196749-74197932:- | HNSC | EER | T_cells_follicular_helper | 6.9057e-04 | -0.1729 |  |
| chrX:74263487-74266556:- | HNSC | EER | B_cells_naive | 1.9335e-02 | 0.1803 |  |
| ENSG00000230590.6,FTX | HNSC | EAG | Macrophages_M2 | 2.0452e-02 | 0.1119 |  |
| ENSG00000230590.6,FTX | KICH | EAG | Mast_cells_resting | 6.0466e-03 | 0.3758 |  |
| chrX:74208227-74208998:- | KIRC | EER | T_cells_CD8 | 4.2446e-02 | 0.2468 |  |
| chrX:74221576-74223936:- | KIRC | EER | T_cells_regulatory_(Tregs) | 8.9246e-03 | -0.3626 | .chrX_74221576-74223936_-.png){kind=small} |
| chrX:74224974-74226827:- | KIRC | EER | T_cells_CD4_memory_activated | 4.5380e-03 | 0.4887 |  |
| chrX:74196749-74197932:- | KIRP | EER | Macrophages_M1 | 3.2554e-02 | 0.1386 |  |
| chrX:74208227-74208998:- | KIRP | EER | Macrophages_M0 | 4.4591e-02 | -0.4321 |  |
| chrX:74221576-74223936:- | KIRP | EER | Macrophages_M1 | 2.9394e-02 | 0.4195 |  |
| ENSG00000230590.6,FTX | KIRP | EAG | Macrophages_M1 | 3.0107e-04 | 0.2246 |  |
| chrX:74196749-74197932:- | LAML | EER | T_cells_CD4_memory_activated | 1.5095e-03 | 0.2577 |  |
| chrX:74208227-74208998:- | LAML | EER | Macrophages_M2 | 2.7052e-02 | 0.1875 |  |
| chrX:74214258-74214491:- | LAML | EER | T_cells_regulatory_(Tregs) | 3.5789e-02 | -0.1880 | .chrX_74214258-74214491_-.png){kind=small} |
| chrX:74216814-74217060:- | LAML | EER | Eosinophils | 2.2309e-02 | 0.2971 |  |
| chrX:74221576-74223936:- | LAML | EER | Macrophages_M1 | 1.0801e-02 | 0.2104 |  |
| chrX:74224974-74226827:- | LAML | EER | Mast_cells_activated | 3.5650e-03 | -0.2430 |  |
| chrX:74243376-74244007:- | LAML | EER | Macrophages_M1 | 3.2028e-03 | 0.3451 |  |
| chrX:74263487-74266556:- | LAML | EER | T_cells_CD4_memory_activated | 3.7665e-02 | 0.1699 |  |
| chrX:74274950-74280179:- | LAML | EER | Macrophages_M2 | 4.2220e-02 | 0.1661 |  |
| ENSG00000230590.6,FTX | LAML | EAG | T_cells_CD4_memory_activated | 2.0593e-04 | 0.2986 |  |
| chrX:74196749-74197932:- | LGG | EER | Macrophages_M1 | 6.3387e-03 | 0.1200 |  |
| chrX:74214258-74214491:- | LGG | EER | T_cells_CD4_memory_resting | 3.2984e-03 | -0.5036 |  |
| chrX:74263487-74266556:- | LGG | EER | T_cells_CD8 | 2.7218e-02 | -0.1322 |  |
| ENSG00000230590.6,FTX | LGG | EAG | Macrophages_M2 | 4.9607e-03 | -0.1226 |  |
| chrX:74196749-74197932:- | LIHC | EER | T_cells_follicular_helper | 6.0348e-03 | -0.1794 |  |
| ENSG00000230590.6,FTX | LIHC | EAG | T_cells_CD4_naive | 3.9575e-02 | -0.1224 |  |
| chrX:74196749-74197932:- | LUAD | EER | T_cells_regulatory_(Tregs) | 2.1249e-03 | -0.1427 | .chrX_74196749-74197932_-.png){kind=small} |
| chrX:74208227-74208998:- | LUAD | EER | B_cells_naive | 1.1036e-02 | 0.2939 |  |
| chrX:74221576-74223936:- | LUAD | EER | Eosinophils | 1.3442e-04 | 0.4241 |  |
| chrX:74224974-74226827:- | LUAD | EER | T_cells_CD4_memory_resting | 7.6053e-05 | -0.4490 |  |
| chrX:74263487-74266556:- | LUAD | EER | Mast_cells_activated | 2.1097e-03 | 0.1591 |  |
| chrX:74274950-74280179:- | LUAD | EER | T_cells_CD8 | 1.0509e-03 | 0.5860 |  |
| ENSG00000230590.6,FTX | LUAD | EAG | T_cells_gamma_delta | 1.5803e-03 | 0.1441 |  |
| chrX:74196749-74197932:- | LUSC | EER | T_cells_follicular_helper | 4.0333e-03 | -0.1426 |  |
| chrX:74208227-74208998:- | LUSC | EER | Mast_cells_activated | 4.0608e-02 | 0.3429 |  |
| chrX:74263487-74266556:- | LUSC | EER | Macrophages_M2 | 3.1368e-02 | 0.1223 |  |
| ENSG00000230590.6,FTX | LUSC | EAG | Plasma_cells | 2.5152e-03 | 0.1409 |  |
| chrX:74196749-74197932:- | MESO | EER | T_cells_gamma_delta | 2.1540e-03 | 0.3402 |  |
| ENSG00000230590.6,FTX | MESO | EAG | T_cells_gamma_delta | 2.0524e-04 | 0.3989 |  |
| chrX:74196749-74197932:- | OV | EER | T_cells_CD8 | 2.0810e-02 | 0.1438 |  |
| chrX:74214258-74214491:- | OV | EER | T_cells_CD8 | 2.1796e-02 | 0.4756 |  |
| chrX:74221576-74223936:- | OV | EER | Dendritic_cells_resting | 2.5010e-02 | -0.1680 |  |
| chrX:74263487-74266556:- | OV | EER | T_cells_CD8 | 2.4783e-03 | 0.1780 |  |
| ENSG00000230590.6,FTX | OV | EAG | T_cells_CD8 | 1.7202e-03 | 0.1842 |  |
| chrX:74196749-74197932:- | PAAD | EER | B_cells_naive | 3.6613e-02 | -0.1619 |  |
| ENSG00000230590.6,FTX | PAAD | EAG | T_cells_CD8 | 3.4476e-02 | -0.1604 |  |
| chrX:74196749-74197932:- | PCPG | EER | T_cells_CD4_memory_activated | 9.9492e-04 | 0.2461 |  |
| chrX:74221576-74223936:- | PCPG | EER | Macrophages_M1 | 2.8597e-02 | 0.3871 |  |
| chrX:74263487-74266556:- | PCPG | EER | Eosinophils | 8.8527e-04 | 0.3502 |  |
| ENSG00000230590.6,FTX | PCPG | EAG | Macrophages_M0 | 4.9695e-02 | 0.1457 |  |
| chrX:74196749-74197932:- | PRAD | EER | Macrophages_M2 | 8.1063e-03 | 0.1219 |  |
| chrX:74221576-74223936:- | PRAD | EER | T_cells_regulatory_(Tregs) | 2.9996e-02 | -0.2161 | .chrX_74221576-74223936_-.png){kind=small} |
| chrX:74263487-74266556:- | PRAD | EER | B_cells_naive | 9.3664e-03 | 0.1467 |  |
| ENSG00000230590.6,FTX | PRAD | EAG | Macrophages_M2 | 3.2132e-03 | 0.1329 |  |
| ENSG00000230590.6,FTX | READ | EAG | Dendritic_cells_resting | 9.7552e-03 | 0.2682 |  |
| chrX:74196749-74197932:- | SARC | EER | Plasma_cells | 1.6750e-02 | 0.1590 |  |
| ENSG00000230590.6,FTX | SARC | EAG | T_cells_CD4_memory_resting | 1.9119e-03 | -0.1981 |  |
| chrX:74196749-74197932:- | SKCM | EER | Neutrophils | 7.6156e-03 | 0.1476 |  |
| chrX:74263487-74266556:- | SKCM | EER | B_cells_memory | 1.0237e-02 | 0.1988 |  |
| ENSG00000230590.6,FTX | SKCM | EAG | Macrophages_M1 | 2.7097e-04 | -0.1900 |  |
| chrX:74196749-74197932:- | STAD | EER | T_cells_CD8 | 1.2795e-02 | 0.1386 |  |
| chrX:74208227-74208998:- | STAD | EER | Neutrophils | 1.3153e-02 | -0.1777 |  |
| chrX:74221576-74223936:- | STAD | EER | B_cells_naive | 3.4590e-02 | 0.1452 |  |
| chrX:74224974-74226827:- | STAD | EER | NK_cells_resting | 5.5423e-03 | 0.1681 |  |
| chrX:74228399-74228673:- | STAD | EER | Macrophages_M0 | 1.1964e-03 | 0.3036 |  |
| chrX:74243376-74244007:- | STAD | EER | NK_cells_resting | 3.7614e-02 | 0.2273 |  |
| chrX:74260775-74262055:- | STAD | EER | Macrophages_M1 | 3.6942e-03 | 0.2529 |  |
| chrX:74263487-74266556:- | STAD | EER | Macrophages_M2 | 2.9222e-03 | 0.1641 |  |
| chrX:74274950-74280179:- | STAD | EER | T_cells_CD4_memory_activated | 1.2346e-06 | 0.3040 |  |
| ENSG00000230590.6,FTX | STAD | EAG | T_cells_CD8 | 4.4762e-06 | 0.2388 |  |
| chrX:74196749-74197932:- | TGCT | EER | T_cells_CD4_memory_activated | 1.2868e-04 | 0.3169 |  |
| chrX:74263487-74266556:- | TGCT | EER | T_cells_CD4_memory_resting | 2.0485e-03 | 0.3004 |  |
| ENSG00000230590.6,FTX | TGCT | EAG | B_cells_naive | 1.5606e-03 | -0.2536 |  |
| chrX:74196749-74197932:- | THCA | EER | Dendritic_cells_activated | 1.2940e-02 | 0.1118 |  |
| chrX:74208227-74208998:- | THCA | EER | B_cells_naive | 4.6926e-02 | 0.2598 |  |
| chrX:74221576-74223936:- | THCA | EER | Neutrophils | 6.6099e-04 | 0.5043 |  |
| chrX:74263487-74266556:- | THCA | EER | B_cells_naive | 1.6787e-03 | 0.1853 |  |
| chrX:74274950-74280179:- | THCA | EER | T_cells_CD4_memory_activated | 1.4470e-03 | 0.4868 |  |
| ENSG00000230590.6,FTX | THCA | EAG | T_cells_regulatory_(Tregs) | 9.9903e-04 | 0.1463 | .ENSG00000230590.6,FTX.png){kind=small} |
| chrX:74196749-74197932:- | THYM | EER | NK_cells_resting | 1.0814e-03 | 0.3191 |  |
| ENSG00000230590.6,FTX | THYM | EAG | NK_cells_resting | 3.2587e-02 | 0.1978 |  |
| chrX:74196749-74197932:- | UCEC | EER | T_cells_CD4_memory_resting | 7.6065e-03 | -0.2247 |  |
| chrX:74224974-74226827:- | UCEC | EER | T_cells_gamma_delta | 3.3119e-03 | 0.4241 |  |
| chrX:74263487-74266556:- | UCEC | EER | Macrophages_M1 | 1.4315e-02 | 0.2299 |  |
| ENSG00000230590.6,FTX | UCEC | EAG | T_cells_gamma_delta | 2.3788e-02 | 0.1733 |  |
| ENSG00000230590.6,FTX | UCS | EAG | B_cells_naive | 2.1117e-02 | 0.3191 |  |
| ENSG00000230590.6,FTX | UVM | EAG | T_cells_CD4_naive | 4.5215e-02 | -0.3145 |  |
Top |
6. Enriched editing regions and immune gene sets for FTX |
 |
| Correlation of enriched editing regions with epithelial-mesenchymal transition. |
| * First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20). |
| * Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20). |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the EERs/EAGs significantly edited between Epi and Mes group. |
| ID_events | cancer | Type | E2M_P | Boxplot | CorP | CorR | CorrelationPlot |
| ENSG00000230590.6,FTX | BLCA | EAG | 8.9423e-03 |  | 2.5449e-09 | 0.2963 |  |
| chrX:74208227-74208998:- | BRCA | EER | 3.7321e-02 |  | 1.4829e-02 | 0.1829 |  |
| chrX:74196749-74197932:- | BRCA | EER | 2.2904e-04 |  | 2.3673e-02 | -0.0695 |  |
| ENSG00000230590.6,FTX | KIRP | EAG | 1.4345e-02 |  | 8.1613e-03 | 0.1653 |  |
Top |
| Correlations of enriched editing regions with hypoxic. |
| * First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method. |
| * Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20). |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page. |
| ID_events | cancer | Type | Buffa_P | Buffa_R | Ragnum_P | Ragnum_R | Winter_P | Winter_R | HALLMARK_P | HALLMARK_R | CorrelationPlot |
| chrX:74224974-74226827:- | BLCA | EER | 4.7667e-03 | 0.2332 | 3.3380e-02 | 0.1768 | 1.6937e-02 | 0.1981 | 3.9714e-02 | 0.1710 |  |
| chrX:74263487-74266556:- | KIRC | EER | 9.1378e-04 | 0.2350 | 1.4078e-02 | 0.1751 | 4.3262e-03 | 0.2030 | 1.9478e-03 | 0.2200 |  |
| chrX:74196749-74197932:- | LUAD | EER | 7.4594e-06 | 0.2070 | 2.0168e-03 | 0.1435 | 6.9099e-04 | 0.1575 | 2.3079e-11 | 0.3048 |  |
| chrX:74263487-74266556:- | LUAD | EER | 2.4649e-04 | 0.1892 | 3.4795e-04 | 0.1847 | 7.9770e-05 | 0.2034 | 1.3931e-06 | 0.2475 |  |
| ENSG00000230590.6,FTX | LUAD | EAG | 3.6774e-03 | 0.1326 | 2.4266e-02 | 0.1030 | 2.1007e-02 | 0.1055 | 6.9236e-06 | 0.2040 |  |
| chrX:74196749-74197932:- | LUSC | EER | 9.4578e-05 | 0.1928 | 4.6993e-02 | 0.0988 | 6.0259e-03 | 0.1362 | 4.2824e-06 | 0.2262 |  |
| ENSG00000230590.6,FTX | LUSC | EAG | 1.7829e-06 | 0.2210 | 3.0273e-02 | 0.1013 | 5.3612e-03 | 0.1299 | 8.7303e-05 | 0.1823 |  |
| chrX:74263487-74266556:- | PRAD | EER | 1.8372e-07 | 0.2896 | 5.9238e-05 | 0.2250 | 5.4158e-06 | 0.2539 | 1.1228e-04 | 0.2166 |  |
| chrX:74224974-74226827:- | STAD | EER | 1.0199e-03 | 0.1985 | 6.5494e-03 | 0.1648 | 7.7726e-03 | 0.1614 | 1.1866e-05 | 0.2626 |  |
| chrX:74274950-74280179:- | STAD | EER | 2.0654e-05 | 0.2684 | 1.9206e-03 | 0.1972 | 3.5239e-03 | 0.1857 | 3.9179e-03 | 0.1837 |  |
| chrX:74263487-74266556:- | STAD | EER | 3.4228e-04 | 0.1968 | 1.6860e-02 | 0.1321 | 4.4731e-03 | 0.1568 | 1.4872e-05 | 0.2370 |  |
Top |
| Associations of enriched editing regions with hallmark gene sets from MSigDB. |
| * P<0.05 and Informative number >=20. |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page. |
| ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
| ENSG00000230590.6,FTX | ACC | GSVA_HALLMARK_INFLAMMATORY_RESPONSE | EAG | 8.2197e-03 | 0.3204 |  |
| chrX:74224974-74226827:- | BLCA | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EER | 2.9472e-03 | 0.2452 |  |
| ENSG00000230590.6,FTX | BLCA | GSVA_HALLMARK_INFLAMMATORY_RESPONSE | EAG | 1.7446e-10 | 0.3163 |  |
| chrX:74221576-74223936:- | BLCA | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 4.3573e-02 | 0.2386 |  |
| chrX:74196749-74197932:- | BLCA | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 1.1998e-08 | 0.2983 |  |
| chrX:74263487-74266556:- | BLCA | GSVA_HALLMARK_HEME_METABOLISM | EER | 4.2821e-08 | 0.3078 |  |
| chrX:74208227-74208998:- | BRCA | GSVA_HALLMARK_GLYCOLYSIS | EER | 7.7253e-04 | 0.2505 |  |
| chrX:74224974-74226827:- | BRCA | GSVA_HALLMARK_HYPOXIA | EER | 1.8134e-07 | 0.4354 |  |
| chrX:74221576-74223936:- | BRCA | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.3143e-05 | 0.3974 |  |
| chrX:74263487-74266556:- | BRCA | GSVA_HALLMARK_HEME_METABOLISM | EER | 1.6864e-13 | 0.3196 |  |
| chrX:74196749-74197932:- | BRCA | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 2.2555e-19 | 0.2716 |  |
| ENSG00000230590.6,FTX | BRCA | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 4.7699e-15 | 0.2355 |  |
| chrX:74274950-74280179:- | BRCA | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 3.9685e-03 | 0.3696 |  |
| ENSG00000230590.6,FTX | CESC | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 1.2004e-06 | 0.2756 |  |
| chrX:74263487-74266556:- | CESC | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 6.0734e-07 | 0.3325 |  |
| chrX:74196749-74197932:- | CESC | GSVA_HALLMARK_GLYCOLYSIS | EER | 7.3236e-05 | 0.2355 |  |
| ENSG00000230590.6,FTX | CHOL | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 2.5679e-02 | -0.3940 |  |
| chrX:74263487-74266556:- | CHOL | GSVA_HALLMARK_DNA_REPAIR | EER | 2.2254e-02 | -0.4742 |  |
| chrX:74196749-74197932:- | CHOL | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 4.8049e-02 | 0.3579 |  |
| ENSG00000230590.6,FTX | COAD | GSVA_HALLMARK_INFLAMMATORY_RESPONSE | EAG | 3.0800e-03 | 0.1843 |  |
| chrX:74263487-74266556:- | COAD | GSVA_HALLMARK_IL2_STAT5_SIGNALING | EER | 1.0908e-07 | 0.4134 |  |
| chrX:74274950-74280179:- | COAD | GSVA_HALLMARK_BILE_ACID_METABOLISM | EER | 1.4509e-02 | 0.5026 |  |
| chrX:74208227-74208998:- | COAD | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 2.0852e-03 | 0.4670 |  |
| chrX:74224974-74226827:- | COAD | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EER | 3.7894e-02 | 0.2687 |  |
| ENSG00000230590.6,FTX | DLBC | GSVA_HALLMARK_TGF_BETA_SIGNALING | EAG | 1.1247e-04 | -0.5549 |  |
| chrX:74208227-74208998:- | ESCA | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 8.1492e-03 | 0.2415 |  |
| chrX:74224974-74226827:- | ESCA | GSVA_HALLMARK_SPERMATOGENESIS | EER | 6.8776e-04 | 0.2796 |  |
| chrX:74221576-74223936:- | ESCA | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.2646e-02 | 0.2118 |  |
| chrX:74263487-74266556:- | ESCA | GSVA_HALLMARK_MTORC1_SIGNALING | EER | 7.3125e-05 | 0.3092 |  |
| chrX:74196749-74197932:- | ESCA | GSVA_HALLMARK_HYPOXIA | EER | 1.9806e-04 | 0.2910 |  |
| ENSG00000230590.6,FTX | ESCA | GSVA_HALLMARK_MYOGENESIS | EAG | 1.1848e-02 | 0.1979 |  |
| chrX:74274950-74280179:- | ESCA | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB | EER | 3.2687e-02 | 0.1868 |  |
| chrX:74228399-74228673:- | ESCA | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 2.8273e-02 | 0.2959 |  |
| chrX:74263487-74266556:- | GBM | GSVA_HALLMARK_HEME_METABOLISM | EER | 2.6973e-05 | 0.3445 |  |
| ENSG00000230590.6,FTX | GBM | GSVA_HALLMARK_ADIPOGENESIS | EAG | 1.4122e-08 | 0.4250 |  |
| chrX:74224974-74226827:- | HNSC | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 3.1103e-02 | 0.2579 |  |
| chrX:74263487-74266556:- | HNSC | GSVA_HALLMARK_INFLAMMATORY_RESPONSE | EER | 6.8235e-04 | 0.2595 |  |
| chrX:74196749-74197932:- | HNSC | GSVA_HALLMARK_GLYCOLYSIS | EER | 1.1691e-08 | 0.2866 |  |
| ENSG00000230590.6,FTX | HNSC | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 2.3257e-05 | 0.2027 |  |
| ENSG00000230590.6,FTX | KICH | GSVA_HALLMARK_HEME_METABOLISM | EAG | 1.2447e-02 | 0.3443 |  |
| chrX:74224974-74226827:- | KIRC | GSVA_HALLMARK_MYC_TARGETS_V2 | EER | 1.9380e-05 | 0.6790 |  |
| chrX:74221576-74223936:- | KIRC | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 6.6884e-03 | 0.3751 |  |
| ENSG00000230590.6,FTX | KIRC | GSVA_HALLMARK_GLYCOLYSIS | EAG | 9.5052e-07 | 0.2556 |  |
| chrX:74214258-74214491:- | KIRC | GSVA_HALLMARK_HYPOXIA | EER | 3.9079e-03 | 0.4516 |  |
| chrX:74263487-74266556:- | KIRC | GSVA_HALLMARK_NOTCH_SIGNALING | EER | 2.0208e-06 | 0.3318 |  |
| chrX:74196749-74197932:- | KIRC | GSVA_HALLMARK_GLYCOLYSIS | EER | 4.4841e-13 | 0.3742 |  |
| chrX:74274950-74280179:- | KIRC | GSVA_HALLMARK_HYPOXIA | EER | 1.2192e-03 | 0.4991 |  |
| chrX:74208227-74208998:- | KIRP | GSVA_HALLMARK_UV_RESPONSE_DN | EER | 4.9010e-03 | -0.5773 |  |
| chrX:74221576-74223936:- | KIRP | GSVA_HALLMARK_ADIPOGENESIS | EER | 4.3712e-02 | -0.3910 |  |
| ENSG00000230590.6,FTX | KIRP | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 6.2623e-06 | 0.2786 |  |
| chrX:74263487-74266556:- | KIRP | GSVA_HALLMARK_ANGIOGENESIS | EER | 5.0595e-04 | 0.2953 |  |
| chrX:74196749-74197932:- | KIRP | GSVA_HALLMARK_ADIPOGENESIS | EER | 5.6941e-11 | 0.4082 |  |
| chrX:74196749-74197932:- | LAML | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 9.6675e-04 | 0.2676 |  |
| chrX:74263487-74266556:- | LAML | GSVA_HALLMARK_MTORC1_SIGNALING | EER | 1.1279e-03 | 0.2634 |  |
| ENSG00000230590.6,FTX | LAML | GSVA_HALLMARK_KRAS_SIGNALING_DN | EAG | 4.9154e-03 | 0.2285 |  |
| chrX:74274950-74280179:- | LAML | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 5.0668e-07 | 0.3966 |  |
| chrX:74208227-74208998:- | LAML | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 1.4343e-03 | -0.2678 |  |
| chrX:74224974-74226827:- | LAML | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 7.4845e-03 | 0.2236 |  |
| chrX:74221576-74223936:- | LAML | GSVA_HALLMARK_IL2_STAT5_SIGNALING | EER | 1.2775e-02 | 0.2056 |  |
| chrX:74214258-74214491:- | LAML | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 7.0643e-04 | 0.2990 |  |
| chrX:74214258-74214491:- | LGG | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 2.3270e-02 | -0.4001 |  |
| chrX:74196749-74197932:- | LGG | GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE | EER | 1.0297e-18 | 0.3754 |  |
| chrX:74263487-74266556:- | LGG | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 6.6029e-09 | 0.3385 |  |
| ENSG00000230590.6,FTX | LGG | GSVA_HALLMARK_KRAS_SIGNALING_DN | EAG | 1.7856e-10 | 0.2740 |  |
| ENSG00000230590.6,FTX | LIHC | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 1.0047e-03 | 0.1945 |  |
| chrX:74263487-74266556:- | LIHC | GSVA_HALLMARK_MTORC1_SIGNALING | EER | 1.8174e-02 | 0.2162 |  |
| chrX:74196749-74197932:- | LIHC | GSVA_HALLMARK_ADIPOGENESIS | EER | 1.2882e-04 | 0.2482 |  |
| chrX:74274950-74280179:- | LUAD | GSVA_HALLMARK_SPERMATOGENESIS | EER | 1.3031e-02 | 0.4633 |  |
| chrX:74208227-74208998:- | LUAD | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EER | 5.4978e-03 | 0.3197 |  |
| chrX:74224974-74226827:- | LUAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 2.0172e-06 | 0.5266 |  |
| chrX:74221576-74223936:- | LUAD | GSVA_HALLMARK_KRAS_SIGNALING_DN | EER | 3.6184e-07 | -0.5448 |  |
| ENSG00000230590.6,FTX | LUAD | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 1.4331e-09 | 0.2723 |  |
| chrX:74263487-74266556:- | LUAD | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 1.4371e-15 | 0.3985 |  |
| chrX:74196749-74197932:- | LUAD | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 2.0300e-16 | 0.3702 |  |
| chrX:74274950-74280179:- | LUSC | GSVA_HALLMARK_HYPOXIA | EER | 1.0273e-02 | -0.4614 |  |
| chrX:74196749-74197932:- | LUSC | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 9.3733e-17 | 0.3972 |  |
| chrX:74263487-74266556:- | LUSC | GSVA_HALLMARK_MTORC1_SIGNALING | EER | 4.4410e-06 | 0.2573 |  |
| ENSG00000230590.6,FTX | LUSC | GSVA_HALLMARK_UV_RESPONSE_UP | EAG | 2.9252e-14 | 0.3452 |  |
| chrX:74263487-74266556:- | MESO | GSVA_HALLMARK_UV_RESPONSE_DN | EER | 1.7312e-03 | 0.4320 |  |
| chrX:74196749-74197932:- | MESO | GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | EER | 4.8710e-02 | 0.2225 |  |
| ENSG00000230590.6,FTX | MESO | GSVA_HALLMARK_COAGULATION | EAG | 1.3840e-03 | 0.3474 |  |
| chrX:74214258-74214491:- | OV | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 2.9276e-03 | 0.5919 |  |
| ENSG00000230590.6,FTX | OV | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 5.1008e-11 | 0.3751 |  |
| chrX:74263487-74266556:- | OV | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 3.0057e-11 | 0.3792 |  |
| chrX:74196749-74197932:- | OV | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 1.7250e-11 | 0.4029 |  |
| chrX:74274950-74280179:- | OV | GSVA_HALLMARK_DNA_REPAIR | EER | 1.3581e-02 | 0.1901 |  |
| chrX:74224974-74226827:- | OV | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 2.7357e-02 | 0.1974 |  |
| chrX:74221576-74223936:- | OV | GSVA_HALLMARK_XENOBIOTIC_METABOLISM | EER | 4.6365e-02 | 0.1495 |  |
| chrX:74263487-74266556:- | PAAD | GSVA_HALLMARK_HEDGEHOG_SIGNALING | EER | 1.9723e-02 | 0.2035 |  |
| chrX:74196749-74197932:- | PAAD | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EER | 6.2548e-06 | 0.3416 |  |
| ENSG00000230590.6,FTX | PAAD | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EAG | 3.0241e-04 | 0.2707 |  |
| chrX:74263487-74266556:- | PCPG | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 4.9890e-03 | 0.2984 |  |
| chrX:74196749-74197932:- | PCPG | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 8.8636e-06 | 0.3280 |  |
| ENSG00000230590.6,FTX | PCPG | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB | EAG | 2.8115e-03 | 0.2202 |  |
| chrX:74224974-74226827:- | PCPG | GSVA_HALLMARK_KRAS_SIGNALING_DN | EER | 2.2949e-02 | -0.4936 |  |
| chrX:74221576-74223936:- | PCPG | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 7.1647e-03 | 0.4662 |  |
| chrX:74224974-74226827:- | PRAD | GSVA_HALLMARK_BILE_ACID_METABOLISM | EER | 7.4508e-04 | 0.3127 |  |
| chrX:74221576-74223936:- | PRAD | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 5.6663e-07 | 0.4736 |  |
| ENSG00000230590.6,FTX | PRAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 3.1658e-06 | 0.2087 |  |
| chrX:74263487-74266556:- | PRAD | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 1.0861e-08 | 0.3161 |  |
| chrX:74196749-74197932:- | PRAD | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 5.1122e-08 | 0.2477 |  |
| ENSG00000230590.6,FTX | READ | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EAG | 1.3431e-03 | 0.3294 |  |
| chrX:74263487-74266556:- | READ | GSVA_HALLMARK_IL2_STAT5_SIGNALING | EER | 7.6613e-04 | 0.4648 |  |
| chrX:74263487-74266556:- | SARC | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 7.3132e-05 | 0.3539 |  |
| chrX:74196749-74197932:- | SARC | GSVA_HALLMARK_HYPOXIA | EER | 5.8647e-08 | 0.3511 |  |
| ENSG00000230590.6,FTX | SARC | GSVA_HALLMARK_XENOBIOTIC_METABOLISM | EAG | 1.3303e-09 | 0.3765 |  |
| ENSG00000230590.6,FTX | SKCM | GSVA_HALLMARK_UV_RESPONSE_UP | EAG | 2.1810e-12 | 0.3576 |  |
| chrX:74263487-74266556:- | SKCM | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 3.6161e-03 | 0.2246 |  |
| chrX:74196749-74197932:- | SKCM | GSVA_HALLMARK_GLYCOLYSIS | EER | 5.5501e-18 | 0.4540 |  |
| chrX:74274950-74280179:- | STAD | GSVA_HALLMARK_DNA_REPAIR | EER | 2.0069e-07 | 0.3248 |  |
| chrX:74228399-74228673:- | STAD | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 2.5407e-06 | 0.4296 |  |
| chrX:74260775-74262055:- | STAD | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 2.1194e-03 | 0.2672 |  |
| chrX:74208227-74208998:- | STAD | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 8.3047e-03 | 0.1890 |  |
| chrX:74224974-74226827:- | STAD | GSVA_HALLMARK_APOPTOSIS | EER | 2.7732e-07 | 0.3060 |  |
| chrX:74221576-74223936:- | STAD | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 8.0294e-03 | 0.1816 |  |
| chrX:74243376-74244007:- | STAD | GSVA_HALLMARK_HYPOXIA | EER | 1.8908e-03 | 0.3342 |  |
| chrX:74263487-74266556:- | STAD | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 1.8985e-08 | 0.3046 |  |
| chrX:74196749-74197932:- | STAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 7.2069e-07 | 0.2720 |  |
| ENSG00000230590.6,FTX | STAD | GSVA_HALLMARK_KRAS_SIGNALING_DN | EAG | 6.3058e-07 | 0.2586 |  |
| ENSG00000230590.6,FTX | TGCT | GSVA_HALLMARK_MITOTIC_SPINDLE | EAG | 2.8304e-08 | -0.4303 |  |
| chrX:74263487-74266556:- | TGCT | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 7.9404e-06 | 0.4243 |  |
| chrX:74196749-74197932:- | TGCT | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 1.7750e-08 | 0.4524 |  |
| chrX:74221576-74223936:- | THCA | GSVA_HALLMARK_TGF_BETA_SIGNALING | EER | 3.1664e-05 | 0.5956 |  |
| ENSG00000230590.6,FTX | THCA | GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE | EAG | 4.4441e-07 | 0.2228 |  |
| chrX:74263487-74266556:- | THCA | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 6.8384e-10 | 0.3550 |  |
| chrX:74196749-74197932:- | THCA | GSVA_HALLMARK_MTORC1_SIGNALING | EER | 6.2294e-13 | 0.3162 |  |
| chrX:74274950-74280179:- | THCA | GSVA_HALLMARK_INFLAMMATORY_RESPONSE | EER | 2.5485e-03 | 0.4642 |  |
| chrX:74208227-74208998:- | THCA | GSVA_HALLMARK_NOTCH_SIGNALING | EER | 2.7028e-04 | 0.4574 |  |
| chrX:74224974-74226827:- | THCA | GSVA_HALLMARK_MYC_TARGETS_V2 | EER | 1.0354e-02 | -0.4468 |  |
| chrX:74263487-74266556:- | THYM | GSVA_HALLMARK_HEME_METABOLISM | EER | 2.9216e-05 | 0.4775 |  |
| chrX:74196749-74197932:- | THYM | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 8.4591e-04 | -0.3254 |  |
| ENSG00000230590.6,FTX | THYM | GSVA_HALLMARK_HEME_METABOLISM | EAG | 7.6805e-05 | -0.3573 |  |
| chrX:74224974-74226827:- | UCEC | GSVA_HALLMARK_UV_RESPONSE_UP | EER | 1.9276e-03 | 0.4453 |  |
| ENSG00000230590.6,FTX | UCEC | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 5.0598e-07 | 0.3740 |  |
| chrX:74263487-74266556:- | UCEC | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 3.1723e-04 | 0.3327 |  |
| chrX:74196749-74197932:- | UCEC | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 7.9101e-07 | 0.4031 |  |
| chrX:74263487-74266556:- | UCS | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.3119e-04 | 0.5809 |  |
| ENSG00000230590.6,FTX | UCS | GSVA_HALLMARK_MYOGENESIS | EAG | 2.2594e-02 | 0.3157 |  |
| chrX:74263487-74266556:- | UVM | GSVA_HALLMARK_MYC_TARGETS_V2 | EER | 3.0360e-03 | 0.6020 |  |
| ENSG00000230590.6,FTX | UVM | GSVA_HALLMARK_KRAS_SIGNALING_DN | EAG | 1.2728e-04 | 0.5630 |  |
Top |
7. Enriched editing regions and drugs for FTX |
 |
| Correlations between enriched editing regions and drug sensitivity. |
| * First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package. |
| * Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20). |
| * EER: enriched editing region, EAG: EER-associated genes. |
| * Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page. |
| ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
| chrX:74263487-74266556:- | ACC | BI.2536 | EER | 1.9023e-03 | 0.5205 |  |
| ENSG00000230590.6,FTX | ACC | BAY.61.3606 | EAG | 1.3521e-04 | 0.4496 |  |
| chrX:74224974-74226827:- | BLCA | Docetaxel | EER | 3.2979e-03 | -0.2425 |  |
| ENSG00000230590.6,FTX | BLCA | KU.55933 | EAG | 1.3799e-10 | -0.3179 |  |
| chrX:74221576-74223936:- | BLCA | AICAR | EER | 4.2963e-02 | -0.2392 |  |
| chrX:74196749-74197932:- | BLCA | CMK | EER | 2.9455e-10 | -0.3282 |  |
| chrX:74263487-74266556:- | BLCA | EHT.1864 | EER | 2.1710e-04 | 0.2106 |  |
| chrX:74208227-74208998:- | BRCA | ATRA | EER | 1.6956e-02 | 0.1803 |  |
| chrX:74224974-74226827:- | BRCA | ABT.263 | EER | 6.0050e-04 | 0.2948 |  |
| chrX:74221576-74223936:- | BRCA | GW843682X | EER | 1.0396e-05 | 0.4016 |  |
| chrX:74263487-74266556:- | BRCA | KIN001.135 | EER | 1.1117e-03 | -0.1444 |  |
| chrX:74196749-74197932:- | BRCA | CCT007093 | EER | 1.9618e-07 | 0.1590 |  |
| ENSG00000230590.6,FTX | BRCA | DMOG | EAG | 7.0568e-06 | 0.1364 |  |
| chrX:74274950-74280179:- | BRCA | BAY.61.3606 | EER | 1.6582e-03 | 0.4008 |  |
| ENSG00000230590.6,FTX | CESC | GNF.2 | EAG | 6.2222e-07 | -0.2826 |  |
| chrX:74263487-74266556:- | CESC | GW843682X | EER | 9.3419e-04 | 0.2241 |  |
| chrX:74196749-74197932:- | CESC | GNF.2 | EER | 4.4468e-04 | -0.2092 |  |
| ENSG00000230590.6,FTX | CHOL | Embelin | EAG | 1.1635e-02 | 0.4405 |  |
| chrX:74263487-74266556:- | CHOL | AMG.706 | EER | 4.9024e-02 | 0.4149 |  |
| chrX:74196749-74197932:- | CHOL | AS601245 | EER | 6.0899e-03 | 0.4816 |  |
| ENSG00000230590.6,FTX | COAD | JNJ.26854165 | EAG | 5.3304e-05 | -0.2498 |  |
| chrX:74263487-74266556:- | COAD | GSK269962A | EER | 5.4268e-03 | -0.2238 |  |
| chrX:74274950-74280179:- | COAD | Bleomycin | EER | 9.8722e-03 | 0.5264 |  |
| chrX:74208227-74208998:- | COAD | BX.795 | EER | 6.4072e-04 | 0.5110 |  |
| chrX:74224974-74226827:- | COAD | Bexarotene | EER | 2.1020e-02 | -0.2974 |  |
| ENSG00000230590.6,FTX | DLBC | A.770041 | EAG | 3.8980e-04 | -0.5167 |  |
| chrX:74263487-74266556:- | DLBC | CI.1040 | EER | 3.5455e-02 | 0.4063 |  |
| chrX:74208227-74208998:- | ESCA | Embelin | EER | 7.4620e-03 | 0.2441 |  |
| chrX:74224974-74226827:- | ESCA | CI.1040 | EER | 3.8933e-02 | 0.1723 |  |
| chrX:74221576-74223936:- | ESCA | AZD.2281 | EER | 1.3510e-03 | 0.2712 |  |
| chrX:74263487-74266556:- | ESCA | BI.D1870 | EER | 2.0253e-03 | -0.2430 |  |
| chrX:74196749-74197932:- | ESCA | Bexarotene | EER | 1.1847e-05 | -0.3397 |  |
| ENSG00000230590.6,FTX | ESCA | AZD8055 | EAG | 3.1198e-03 | -0.2316 |  |
| chrX:74274950-74280179:- | ESCA | KU.55933 | EER | 6.1883e-04 | -0.2952 |  |
| chrX:74228399-74228673:- | ESCA | KU.55933 | EER | 8.1491e-04 | -0.4422 |  |
| chrX:74260775-74262055:- | ESCA | GNF.2 | EER | 9.9573e-03 | -0.2660 |  |
| chrX:74263487-74266556:- | GBM | GDC.0449 | EER | 3.5969e-03 | 0.2428 |  |
| ENSG00000230590.6,FTX | GBM | BIRB.0796 | EAG | 2.9358e-07 | 0.3876 |  |
| chrX:74263487-74266556:- | HNSC | BMS.708163 | EER | 1.7989e-03 | -0.2391 |  |
| chrX:74196749-74197932:- | HNSC | AZD.0530 | EER | 1.1432e-04 | -0.1961 |  |
| ENSG00000230590.6,FTX | HNSC | AZD6482 | EAG | 2.1434e-08 | 0.2662 |  |
| chrX:74208227-74208998:- | KIRC | BIRB.0796 | EER | 2.0986e-02 | -0.2795 |  |
| chrX:74224974-74226827:- | KIRC | CCT007093 | EER | 3.9302e-04 | 0.5888 |  |
| chrX:74221576-74223936:- | KIRC | Embelin | EER | 3.0687e-03 | -0.4066 |  |
| ENSG00000230590.6,FTX | KIRC | GNF.2 | EAG | 1.2150e-05 | -0.2289 |  |
| chrX:74214258-74214491:- | KIRC | ABT.263 | EER | 2.3133e-03 | 0.4738 |  |
| chrX:74263487-74266556:- | KIRC | Bexarotene | EER | 4.1261e-03 | -0.2040 |  |
| chrX:74196749-74197932:- | KIRC | GNF.2 | EER | 5.5398e-08 | -0.2854 |  |
| chrX:74274950-74280179:- | KIRC | ATRA | EER | 9.0033e-03 | 0.4128 |  |
| chrX:74208227-74208998:- | KIRP | Cyclopamine | EER | 2.4697e-04 | -0.7052 |  |
| ENSG00000230590.6,FTX | KIRP | BIBW2992 | EAG | 4.8584e-07 | 0.3089 |  |
| chrX:74263487-74266556:- | KIRP | AZD6244 | EER | 2.1680e-02 | 0.1975 |  |
| chrX:74196749-74197932:- | KIRP | Bosutinib | EER | 2.0224e-08 | 0.3537 |  |
| chrX:74196749-74197932:- | LAML | Dasatinib | EER | 1.3629e-03 | -0.2600 |  |
| chrX:74216814-74217060:- | LAML | Cyclopamine | EER | 7.0486e-03 | 0.3472 |  |
| chrX:74263487-74266556:- | LAML | CCT007093 | EER | 1.2532e-03 | 0.2610 |  |
| ENSG00000230590.6,FTX | LAML | CGP.082996 | EAG | 1.3125e-03 | -0.2600 |  |
| chrX:74274950-74280179:- | LAML | CCT007093 | EER | 2.8818e-08 | 0.4340 |  |
| chrX:74208227-74208998:- | LAML | Gefitinib | EER | 7.2218e-03 | 0.2269 |  |
| chrX:74224974-74226827:- | LAML | Embelin | EER | 2.3230e-03 | 0.2536 |  |
| chrX:74221576-74223936:- | LAML | CGP.082996 | EER | 4.6744e-03 | -0.2329 |  |
| chrX:74243376-74244007:- | LAML | BX.795 | EER | 9.7673e-03 | -0.3047 |  |
| chrX:74214258-74214491:- | LAML | Imatinib | EER | 2.2983e-05 | 0.3689 |  |
| chrX:74214258-74214491:- | LGG | A.443654 | EER | 5.0144e-03 | 0.4839 |  |
| chrX:74196749-74197932:- | LGG | Doxorubicin | EER | 2.8311e-14 | 0.3264 |  |
| chrX:74263487-74266556:- | LGG | GW843682X | EER | 8.5419e-09 | 0.3361 |  |
| ENSG00000230590.6,FTX | LGG | Doxorubicin | EAG | 1.0124e-09 | 0.2627 |  |
| ENSG00000230590.6,FTX | LIHC | CCT007093 | EAG | 3.0114e-04 | 0.2133 |  |
| chrX:74196749-74197932:- | LIHC | Lenalidomide | EER | 2.3466e-02 | 0.1487 |  |
| chrX:74274950-74280179:- | LUAD | Elesclomol | EER | 6.5334e-04 | -0.6047 |  |
| chrX:74208227-74208998:- | LUAD | FH535 | EER | 2.9065e-02 | -0.2539 |  |
| chrX:74224974-74226827:- | LUAD | BMS.509744 | EER | 2.5982e-05 | -0.4740 |  |
| chrX:74221576-74223936:- | LUAD | Bexarotene | EER | 1.0941e-07 | 0.5644 |  |
| ENSG00000230590.6,FTX | LUAD | Cisplatin | EAG | 9.4799e-03 | -0.1186 |  |
| chrX:74263487-74266556:- | LUAD | CMK | EER | 3.2769e-04 | -0.1855 |  |
| chrX:74196749-74197932:- | LUAD | BMS.509744 | EER | 1.3386e-05 | -0.2012 |  |
| chrX:74274950-74280179:- | LUSC | AMG.706 | EER | 6.0268e-03 | 0.4896 |  |
| chrX:74208227-74208998:- | LUSC | Docetaxel | EER | 3.3027e-02 | -0.3561 |  |
| chrX:74196749-74197932:- | LUSC | MG.132 | EER | 1.8936e-10 | -0.3100 |  |
| chrX:74263487-74266556:- | LUSC | CGP.082996 | EER | 2.1811e-03 | -0.1734 |  |
| ENSG00000230590.6,FTX | LUSC | MG.132 | EAG | 1.5729e-09 | -0.2776 |  |
| chrX:74263487-74266556:- | MESO | GW843682X | EER | 4.2538e-04 | 0.4796 |  |
| chrX:74196749-74197932:- | MESO | A.770041 | EER | 1.0538e-04 | -0.4224 |  |
| ENSG00000230590.6,FTX | MESO | BMS.536924 | EAG | 2.8954e-05 | -0.4443 |  |
| chrX:74214258-74214491:- | OV | JNK.9L | EER | 7.0803e-03 | 0.5456 |  |
| ENSG00000230590.6,FTX | OV | BAY.61.3606 | EAG | 1.9519e-08 | 0.3240 |  |
| chrX:74263487-74266556:- | OV | BAY.61.3606 | EER | 7.5379e-06 | 0.2609 |  |
| chrX:74196749-74197932:- | OV | A.770041 | EER | 1.4716e-10 | -0.3853 |  |
| chrX:74274950-74280179:- | OV | ABT.263 | EER | 7.7329e-03 | 0.2048 |  |
| chrX:74208227-74208998:- | OV | GDC0941 | EER | 3.2997e-02 | 0.2113 |  |
| chrX:74224974-74226827:- | OV | BI.2536 | EER | 1.8339e-02 | 0.2107 |  |
| chrX:74221576-74223936:- | OV | Cyclopamine | EER | 7.3262e-04 | 0.2508 |  |
| chrX:74263487-74266556:- | PAAD | Cisplatin | EER | 3.5676e-04 | 0.3073 |  |
| chrX:74196749-74197932:- | PAAD | AZD6482 | EER | 1.7096e-03 | 0.2438 |  |
| ENSG00000230590.6,FTX | PAAD | ATRA | EAG | 7.5159e-03 | 0.2050 |  |
| chrX:74263487-74266556:- | PCPG | GW843682X | EER | 5.3023e-03 | 0.2964 |  |
| chrX:74196749-74197932:- | PCPG | Lenalidomide | EER | 2.3039e-05 | 0.3132 |  |
| ENSG00000230590.6,FTX | PCPG | Camptothecin | EAG | 5.7152e-03 | -0.2041 |  |
| chrX:74224974-74226827:- | PCPG | Bryostatin.1 | EER | 8.5678e-04 | -0.6716 |  |
| chrX:74221576-74223936:- | PCPG | Bosutinib | EER | 1.8704e-03 | 0.5286 |  |
| chrX:74224974-74226827:- | PRAD | KIN001.135 | EER | 1.6341e-04 | -0.3474 |  |
| chrX:74221576-74223936:- | PRAD | Bryostatin.1 | EER | 6.7170e-05 | 0.3860 |  |
| ENSG00000230590.6,FTX | PRAD | Embelin | EAG | 9.6585e-06 | 0.1984 |  |
| chrX:74263487-74266556:- | PRAD | Bryostatin.1 | EER | 3.2624e-03 | 0.1658 |  |
| chrX:74196749-74197932:- | PRAD | DMOG | EER | 1.0906e-06 | 0.2224 |  |
| ENSG00000230590.6,FTX | READ | ABT.263 | EAG | 2.2526e-03 | 0.3163 |  |
| chrX:74196749-74197932:- | SARC | Cisplatin | EER | 6.0617e-07 | -0.3246 |  |
| ENSG00000230590.6,FTX | SARC | BMS.536924 | EAG | 7.4596e-12 | -0.4217 |  |
| ENSG00000230590.6,FTX | SKCM | CCT007093 | EAG | 3.4766e-08 | 0.2845 |  |
| chrX:74263487-74266556:- | SKCM | Bexarotene | EER | 1.3883e-02 | 0.1906 |  |
| chrX:74196749-74197932:- | SKCM | CCT007093 | EER | 3.4466e-08 | 0.2997 |  |
| chrX:74274950-74280179:- | STAD | Cisplatin | EER | 6.4638e-05 | -0.2524 |  |
| chrX:74228399-74228673:- | STAD | AG.014699 | EER | 4.6162e-05 | 0.3766 |  |
| chrX:74260775-74262055:- | STAD | DMOG | EER | 7.3708e-04 | 0.2924 |  |
| chrX:74208227-74208998:- | STAD | Bortezomib | EER | 2.7293e-04 | 0.2585 |  |
| chrX:74224974-74226827:- | STAD | Bortezomib | EER | 3.2981e-05 | -0.2494 |  |
| chrX:74221576-74223936:- | STAD | A.770041 | EER | 5.2050e-03 | 0.1917 |  |
| chrX:74243376-74244007:- | STAD | JNK.9L | EER | 9.2495e-04 | 0.3549 |  |
| chrX:74263487-74266556:- | STAD | Methotrexate | EER | 5.8378e-03 | -0.1526 |  |
| chrX:74196749-74197932:- | STAD | CCT007093 | EER | 4.7740e-06 | 0.2518 |  |
| ENSG00000230590.6,FTX | STAD | BMS.536924 | EAG | 1.7860e-07 | -0.2705 |  |
| ENSG00000230590.6,FTX | TGCT | MG.132 | EAG | 2.2812e-07 | -0.4037 |  |
| chrX:74263487-74266556:- | TGCT | AZD6482 | EER | 8.9782e-04 | -0.3224 |  |
| chrX:74196749-74197932:- | TGCT | Cyclopamine | EER | 6.9571e-10 | -0.4900 |  |
| chrX:74221576-74223936:- | THCA | AMG.706 | EER | 4.1188e-05 | 0.5887 |  |
| ENSG00000230590.6,FTX | THCA | CI.1040 | EAG | 5.7483e-09 | -0.2560 |  |
| chrX:74263487-74266556:- | THCA | AMG.706 | EER | 6.5853e-08 | 0.3133 |  |
| chrX:74196749-74197932:- | THCA | IPA.3 | EER | 1.0221e-11 | 0.2998 |  |
| chrX:74274950-74280179:- | THCA | AMG.706 | EER | 3.1607e-02 | 0.3404 |  |
| chrX:74208227-74208998:- | THCA | AZD7762 | EER | 5.4215e-03 | -0.3576 |  |
| chrX:74224974-74226827:- | THCA | Metformin | EER | 1.9322e-02 | 0.4114 |  |
| chrX:74263487-74266556:- | THYM | JNK.Inhibitor.VIII | EER | 1.4221e-04 | -0.4393 |  |
| chrX:74196749-74197932:- | THYM | DMOG | EER | 2.2845e-05 | 0.4061 |  |
| ENSG00000230590.6,FTX | THYM | AZD6482 | EAG | 4.9896e-04 | 0.3169 |  |
| chrX:74224974-74226827:- | UCEC | Bosutinib | EER | 4.9271e-03 | 0.4076 |  |
| ENSG00000230590.6,FTX | UCEC | AG.014699 | EAG | 1.4980e-04 | 0.2868 |  |
| chrX:74263487-74266556:- | UCEC | FH535 | EER | 5.6541e-04 | -0.3194 |  |
| chrX:74196749-74197932:- | UCEC | DMOG | EER | 2.1972e-04 | 0.3075 |  |
| chrX:74263487-74266556:- | UCS | FH535 | EER | 3.7751e-04 | -0.5472 |  |
| ENSG00000230590.6,FTX | UCS | GNF.2 | EAG | 2.0720e-04 | -0.4926 |  |
| chrX:74263487-74266556:- | UVM | BI.D1870 | EER | 1.1233e-02 | -0.5297 |  |
| ENSG00000230590.6,FTX | UVM | GNF.2 | EAG | 3.9057e-04 | -0.5278 |  |
Top |
| EAGs targeted by drugs from DrugBank database. |
| * EAG: EER-associated genes. |
| EER | ENST | UniprotID | DrugBankID | Drug | DrugType |
